SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments

Multiple myeloma (MM) is a common hematological malignancy that has fostered several new therapeutic approaches to combat newly diagnosed or relapsed MM. While the field has advanced over the past 2 decades, the majority of patients will develop resistance to these treatments, causing the need for n...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Emily, Wu, Jian, Kang, Stacey S., Kang, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529721/
https://www.ncbi.nlm.nih.gov/pubmed/37754488
http://dx.doi.org/10.3390/curroncol30090573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529721/
https://www.ncbi.nlm.nih.gov/pubmed/37754488
http://dx.doi.org/10.3390/curroncol30090573

Ejemplares similares